Skip to main content
Onconetix, Inc. logo

Onconetix, Inc. — Investor Relations & Filings

Ticker · ONCO ISIN · US68237Q1040 US Manufacturing
Filings indexed 342 across all filing types
Latest filing 2026-05-19 Share Issue/Capital Cha…
Country US United States of America
Listing US ONCO

About Onconetix, Inc.

https://www.onconetix.com/

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of proprietary solutions. The company develops therapeutics, diagnostics, and services primarily for men's health and oncology.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Share Issue/Capital Change Classification · 85% confidence The document is a Current Report on Form 8-K disclosing Item 5.03—the approval and implementation of a 1-for-10 reverse stock split (a change in the company’s capital structure through a stock split). It does not contain full financial statements or earnings data, nor is it merely a publication announcement. It is a notification of a capital change (reverse stock split). Under the classification definitions, announcements of stock splits and other capital changes fall under Share Issue/Capital Change (SHA).
2026-05-19 English
CURRENT REPORT
Regulatory Filings Classification · 90% confidence The document is a U.S. SEC Form 8-K “Current Report” under Section 13 or 15(d) of the Exchange Act, with Items 8.01 (Other Events) and 9.01 (Exhibits) describing a press release being furnished as Exhibit 99.1. It does not contain actual financial statements or detailed periodic results but is a regulatory filing of an 8-K. This fits the catch‐all category for miscellaneous regulatory announcements.
2026-05-13 English
10-Q - Onconetix, Inc. (0001782107) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
S-1/A - Onconetix, Inc. (0001782107) (Filer)
Regulatory Filings
2026-05-07 English
8-K - Onconetix, Inc. (0001782107) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 24, 2026, reporting changes in the company's board of directors and officers. It details the resignation of two directors and the election of a new chairman and a new board member, including their roles and compensation. There is no financial data or earnings information presented. The primary content is about management and board changes, which fits the category of Board/Management Information (MANG). The document length is 8193 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the appropriate classification is MANG with high confidence.
2026-04-24 English
DEF 14A - Onconetix, Inc. (0001782107) (Filer)
Proxy Solicitation & Information Statement
2026-03-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.